BETA: Please send your feedback!
Celldex Therapeutics
CLDX:NAS
Biotechnology
$35.59mm
SMALL cap
$2.37
(0.01%)
-0.37%
since start of 2019
-0.64
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 1
-
CF
-
PP
-
WC
-
DP
-
CH
-
ES
-
WS
-
CG
-
EP
-
CM
-
FL
-
GD
- —
- 1
- 2
- 3
- 4
- 5
About
Biotechnology
Founded 1983
Celldex Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes therapeutic antibodies, antibody drug conjugates, vaccines, and immune system modulators. The company's drug candidates include Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, and Rintega. Celldex Therapeutics was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
website
Headquarters
Executives
| Name | Title | Gender |
| Thomas Andrew Davis, MD | Chief Medical Officer & Executive Vice President | Male |
| Avery W. Catlin, MBA, CPA | CFO, Secretary, Treasurer & Senior Vice President | Male |
| Larry Ellberger | Chairman | Male |
| Anthony S. Marucci, MBA | President, Chief Executive Officer & Director | Male |
| Tibor Keler, PhD | Chief Scientific Officer & Executive VP | Male |
| Sarah Boylan Cavanaugh | VP-Investor Relations & Corporate Communications | Female |
| Theresa M. LaVallee, PhD | Senior VP-Regulatory & Precision Medicine | Female |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
-
Carbon Footprint — N/A
-
Pollution Prevention — N/A
-
Water Conservation — N/A
-
Data & Privacy Protection — N/A
-
Consumer Health, Wellness & Safety — N/A
-
Employee Ownership, Satisfaction, Benefits & Pay — N/A
-
Workplace Health and Safety — N/A
-
Integrity of Corporate Governance — N/A
-
Ethical Practices — N/A
-
Usage of Conflict Materials — N/A
-
Forced Labor — N/A
-
Diversity of Corporate Leadership 2
Celldex Therapeutics - Competitors and Related Companies
How Celldex Therapeutics stacks up to its peers in the Biotechnology industry or with competing business segments.
Celldex Therapeutics
CLDX:NAS
Biotechnology
$35.59mm
SMALL cap
$2.37
(0.01%)
-0.37%
since start of 2019
-0.64
Agenus
AGEN:NAS
Biotechnology
$350.83mm
SMALL cap
$2.56
(-0.07%)
0.02%
since start of 2019
-2.77
Emergent BioSolutions
EBS:NYS
Biotechnology
$2.69bn
MID cap
$52.07
(-2.84%)
-0.10%
since start of 2019
-152.79
Seattle Genetics
SGEN:NAS
Biotechnology
$17.04bn
MID cap
$100.92
(13.52%)
0.67%
since start of 2019
-57.94
GlaxoSmithKline
GSK-GB:LON
Pharmaceuticals: Major
$105.41bn
MEGA cap
$42.60
(0.07%)
0.12%
since start of 2019
18.32
Pfizer
PFE:NYS
Pharmaceuticals: Major
$201.66bn
MEGA cap
$36.46
(0.00%)
-0.16%
since start of 2019
16.35